Biosergen AB Stock price

Equities

BIOSGN

SE0016013460

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 06:44:09 2024-03-28 am EDT 5-day change 1st Jan Change
0.442 SEK -3.49% Intraday chart for Biosergen AB +13.33% -49.77%
Sales 2024 * - Sales 2025 * 257M 24.1M Capitalization 61.23M 5.73M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net Debt 2024 * 63.1M 5.91M Net Debt 2025 * 288M 26.95M EV / Sales 2025 * 1.36 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 3
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.89%
More Fundamentals * Assessed data
Dynamic Chart
Biosergen Raises SEK26.4 Million via Rights Issue MT
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy MT
Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection CI
Biosergen Seeks Fresh Funds from Rights Offering, Secures Loan from Major Shareholder MT
Biosergen AB Announces CEO Changes CI
Biosergen AB Announces Transition of Peder M. Andersen into A Chief Medical Officer Role CI
Biosergen Conducts A New Phase 1B Study in Patients with Invasive Fungal Infections with Its Drug Candidate Bsg005 Together with Alkem CI
Biosergen's Indian Partner Seeks Approval for Clinical Trial of Antifungal Drug Candidate MT
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Biosergen AB Announces Abstract About the Drug Candidate BSG005 CI
Certain Shares of Biosergen AB are subject to a Lock-Up Agreement Ending on 4-OCT-2023. CI
Biosergen, Alkem Laboratories Partner to Launch Clinical Trial of Fungal Disease Treatment in India MT
Alkem Laboratories Limited and Biosergen AB Enter into a Co-Development and License Agreement CI
Biosergen AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news
1 day-3.49%
1 week+13.33%
Current month-40.27%
1 month-40.67%
3 months-50.61%
6 months-64.64%
Current year-49.77%
More quotes
1 week
0.43
Extreme 0.432
0.50
1 month
0.27
Extreme 0.272
0.75
Current year
0.27
Extreme 0.272
1.08
1 year
0.27
Extreme 0.272
1.99
3 years
0.27
Extreme 0.272
23.00
5 years
0.27
Extreme 0.272
23.00
10 years
0.27
Extreme 0.272
23.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 68 -
Chief Tech/Sci/R&D Officer 72 -
Members of the board TitleAgeSince
Director/Board Member 66 20-12-31
Director/Board Member 66 20-12-31
Chairman 65 14-12-31
More insiders
Date Price Change Volume
24-03-28 0.442 -3.49% 6,793
24-03-27 0.458 +3.15% 51,126
24-03-26 0.444 -5.93% 73,769
24-03-25 0.472 -3.28% 57,538
24-03-22 0.488 +25.13% 169,629

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 06:44 am EDT

More quotes
Biosergen AB is a Sweden-based biotechnology company. It carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The Company is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Biosergen AB - Nasdaq Stockholm